Actelion's Tracleer Hangs On, Uptravi Launch Begins

Some good luck and transition in its portfolio has Actelion ahead of analysts' estimates and projecting a strong year for its PAH franchise as it launches its latest product. A delay in generics for its old blockbuster is giving its two newest products time to find their footing.

Europe's largest biotech announced fourth quarter and full year earnings Feb. 9 that turned out to be a pleasant surprise...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Cardiovascular

More from Therapeutic Category